ADMA Biologics Inc Common Stock ADMA
i
Market dataready · fetched 2026-11-03T22:09:11.807Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:27:01.609129215Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-03T22:09:11.118049+00:00
ADMA Biologics Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.39 | 113.4% | 19.4% | |||
| 25Δ | 9.77 | 116.5% | 17.2% | |||
| 30Δ | 12.60 | 84.0% | 15.6% | 10.13 | 116.1% | 15.0% |
| 35Δ | 12.17 | 77.8% | 12.3% | 10.49 | 109.6% | 12.7% |
| 40Δ | 11.86 | 74.1% | 10.1% | 10.85 | 103.0% | 10.3% |
| 45Δ | 11.62 | 72.0% | 8.7% | 11.13 | 96.5% | 8.6% |
| 50Δ | 11.39 | 69.9% | 7.3% | 11.36 | 90.1% | 7.2% |
| 55Δ | 11.16 | 67.8% | 5.8% | 11.60 | 83.6% | 5.8% |
| 60Δ | 10.90 | 69.3% | 4.8% | |||
| 65Δ | 10.59 | 77.7% | 4.4% | 13.38 | 153.2% | 6.7% |
| 70Δ | 10.29 | 86.1% | 4.0% | 13.67 | 139.3% | 5.1% |
| 75Δ | 9.98 | 94.2% | 3.5% | 13.95 | 125.4% | 3.4% |
| 80Δ | 9.62 | 93.4% | 2.7% | 15.45 | 147.4% | 2.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.39
- IV
- 113.4%
- B/E move
- 19.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.77
- IV
- 116.5%
- B/E move
- 17.2%
30Δ
- Pseudo strike
- 12.60
- IV
- 84.0%
- B/E move
- 15.6%
- Pseudo strike
- 10.13
- IV
- 116.1%
- B/E move
- 15.0%
35Δ
- Pseudo strike
- 12.17
- IV
- 77.8%
- B/E move
- 12.3%
- Pseudo strike
- 10.49
- IV
- 109.6%
- B/E move
- 12.7%
40Δ
- Pseudo strike
- 11.86
- IV
- 74.1%
- B/E move
- 10.1%
- Pseudo strike
- 10.85
- IV
- 103.0%
- B/E move
- 10.3%
45Δ
- Pseudo strike
- 11.62
- IV
- 72.0%
- B/E move
- 8.7%
- Pseudo strike
- 11.13
- IV
- 96.5%
- B/E move
- 8.6%
50Δ
- Pseudo strike
- 11.39
- IV
- 69.9%
- B/E move
- 7.3%
- Pseudo strike
- 11.36
- IV
- 90.1%
- B/E move
- 7.2%
55Δ
- Pseudo strike
- 11.16
- IV
- 67.8%
- B/E move
- 5.8%
- Pseudo strike
- 11.60
- IV
- 83.6%
- B/E move
- 5.8%
60Δ
- Pseudo strike
- 10.90
- IV
- 69.3%
- B/E move
- 4.8%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 10.59
- IV
- 77.7%
- B/E move
- 4.4%
- Pseudo strike
- 13.38
- IV
- 153.2%
- B/E move
- 6.7%
70Δ
- Pseudo strike
- 10.29
- IV
- 86.1%
- B/E move
- 4.0%
- Pseudo strike
- 13.67
- IV
- 139.3%
- B/E move
- 5.1%
75Δ
- Pseudo strike
- 9.98
- IV
- 94.2%
- B/E move
- 3.5%
- Pseudo strike
- 13.95
- IV
- 125.4%
- B/E move
- 3.4%
80Δ
- Pseudo strike
- 9.62
- IV
- 93.4%
- B/E move
- 2.7%
- Pseudo strike
- 15.45
- IV
- 147.4%
- B/E move
- 2.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 66.85% | |
| 66.71% | |
| 52.95% | |
| 69.23% | |
| 57.33% | |
| 54.63% | |
| 71.35% | |
| 80.77% | |
| 53.11% | |
| 53.56% | |
| 48.35% | |
| 50.33% | |
| 49.19% | |
| 49.77% | |
| 53.59% | |
| 52.18% | |
| 56.80% | |
| 70.43% | |
| 72.14% | |
| 83.00% | |
| 75.23% | |
| 81.51% | |
| 65.23% | |
| 56.96% | |
| 59.73% | |
| 60.00% | |
| 52.71% | |
| 68.58% | |
| 79.53% | |
| 61.18% | |
| 66.78% | |
| 64.43% | |
| 71.06% | |
| 84.29% | |
| 78.25% | |
| 83.31% | |
| 93.22% | |
| 88.49% | |
| 104.44% | |
| 106.75% | |
| 97.83% | |
| 76.54% | |
| 77.89% | |
| 60.48% | |
| 61.42% | |
| 63.80% | |
| 58.82% | |
| 66.78% | |
| 74.00% | |
| 70.14% | |
| 60.86% | |
| 59.71% |
Biotechnology
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in…
More →AGIO
Description unavailable
More →AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve…
More →ALDX
Description unavailable
More →ALEC
Description unavailable
More →